Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation

Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation

Abstract Background/Purpose Little is known about long-term clinical outcomes or urate-lowering (ULT) therapy use following pegloticase discontinuation. We examined ULT use, serum urate (SU), inflammatory biomarkers, and renal function following pegloticase discontinuation. Methods We conducted a re...

Full description

Bibliographic Details
Main Authors: Emily E. Holladay, Amy S. Mudano, Fenglong Xie, Jingyi Zhang, Ted R. Mikuls, Brian LaMoreaux, Lissa Padnick-Silver, Jeffrey R. Curtis
Format: Article
Language:English
Published: BMC 2024-04-01
Series:Arthritis Research & Therapy
Subjects:
Gout
Pegloticase
Treatment gap
Restart
Discontinuation
Online Access:https://doi.org/10.1186/s13075-024-03318-5

Similar Items

Similar Items